Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CPIX | 8-K | neutral | 5/10 | Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban as a treatmen | Oct 26, 2026 |
| SLBT | 6-K | neutral | 4/10 | SL Science Holding Ltd (SLBT) filed its unaudited H1 2026 financial results via Form 6-K, reporting revenue of $1.39M (u | Oct 26, 2026 |
| CTY | SC 13D | neutral | 5/10 | ARCH Venture Fund XII, L.P. and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 13,692,507 s | Oct 26, 2026 |
| MCRB | 8-K | bearish | 5/10 | Seres Therapeutics CFO Marella Thorell resigned effective November 15, 2026, and will provide advisory services for an o | Oct 26, 2026 |
| GLSI | DEF 14A | neutral | 3/10 | Greenwich LifeSciences filed its definitive proxy statement for the 2026 annual meeting. The filing is routine: it propo | Oct 26, 2026 |
| CTY | SC 13G | neutral | 4/10 | Viking Global Investors LP and affiliated entities filed a Schedule 13G disclosing a passive 7% stake in City Therapeuti | Oct 26, 2026 |
| MEDP | 144 | neutral | 2/10 | Susan E. Burwig, an officer of Medpace Holdings, filed a Form 144 notice of intent to sell 16,060 shares of common stock | Oct 26, 2026 |
| ABOS | S-3 | bearish | 5/10 | Acumen Pharmaceuticals filed a universal shelf registration statement (S-3) on October 26, 2026, registering an unlimite | Oct 26, 2026 |
| PRTA | INSIDER-BUY | bullish | 5/10 | Prothena director and 10% owner William Scully purchased $819K in open-market shares on October 22, 2026, at $8.19 per s | Oct 26, 2026 |
| ALEC | SC 13G | neutral | 4/10 | RA Capital Management, L.P. and affiliated entities filed a Schedule 13G disclosing a new 5.1% passive stake in Alector, | Oct 26, 2026 |
| SNTI | 8-K | bearish | 7/10 | Senti Biosciences completed its merger with a Celadon Partners affiliate, divesting its operating subsidiary (Midco/Opco | Oct 26, 2026 |
| ETST | 8-K | neutral | 3/10 | Earth Science Tech, Inc. announced the resignation of CFO and board member Ernesto L. Flores, effective October 25, 2026 | Oct 26, 2026 |
| SLBT | PRESS-RELEASE | neutral | 4/10 | SL Science reported H1 2026 revenue of $1.39M (+23% YoY) and a net loss of $2.16M, widening from $1.60M. The company hig | Oct 26, 2026 |
| LYCA | PRESS-RELEASE | neutral | 5/10 | Lycia Therapeutics closed its upsized initial public offering of 20,286,000 shares at $18.00 per share, raising approxim | Oct 26, 2026 |
| ZYME | DEFA14A | neutral | 2/10 | Zymeworks Inc. filed a DEFA14A notice of internet availability of proxy materials for its 2026 annual meeting of stockho | Oct 26, 2026 |
| ZYME | DEF 14A | neutral | 3/10 | Zymeworks Inc. filed its definitive proxy statement for the 2026 annual meeting of stockholders to be held on December 1 | Oct 26, 2026 |
| AGIO | 144 | neutral | 2/10 | Sarah Gheuens, an officer of Agios Pharmaceuticals, filed a Form 144 notice of intent to sell 7,866 shares of common sto | Oct 26, 2026 |
| TPST | DEF 14A | bearish | 6/10 | Tempest Therapeutics' 2026 definitive proxy statement schedules a November 9, 2026 annual meeting with four proposals: e | Oct 26, 2026 |
| SAFX | DEF 14A | bearish | 6/10 | XCF Global (SAFX) is holding a special meeting on November 9, 2026 to approve a reverse stock split (1-for-2 to 1-for-50 | Oct 26, 2026 |
| CTXR | 8-K | neutral | 4/10 | Citius Oncology reported preliminary Q4 FY2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 360 uni | Oct 26, 2026 |
| CTOR | 8-K | neutral | 5/10 | Citius Oncology reported preliminary fiscal Q4 2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 36 | Oct 26, 2026 |
| JAZZ | 8-K | bearish | 6/10 | Jazz Pharmaceuticals filed an 8-K estimating a pre-tax charge of approximately $755 million for acquired IPR&D expense r | Oct 26, 2026 |
| ASND | 6-K | bullish | 5/10 | Ascendis Pharma announced pooled data from Phase 2 and Phase 3 trials showing TransCon PTH (palopegteriparatide) provide | Oct 26, 2026 |
| SPRC | 6-K | bearish | 5/10 | SciSparc entered into an inducement letter with L.I.A Pure Capital to exercise warrants for 405,728 shares at a reduced | Oct 26, 2026 |
| SNY | SC 13G/A | neutral | 2/10 | Amundi filed an amended Schedule 13G disclosing a 5.70% passive stake in Sanofi as of September 30, 2026, up from 5.50% | Oct 26, 2026 |
| LONA | SC 13D/A | neutral | 3/10 | Perceptive Advisors LLC filed an amended Schedule 13D disclosing that its affiliate, Perceptive Xontogeny Venture Fund I | Oct 26, 2026 |
| SAFX | 3 | neutral | 1/10 | Chad J. Langley filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing no securities benef | Oct 26, 2026 |
| HELP | 3 | neutral | 2/10 | Freda C. Lewis-Hall filed a Form 3 initial statement of beneficial ownership after becoming a director of Helus Pharma I | Oct 26, 2026 |
| CTOR | PRESS-RELEASE | neutral | 4/10 | Citius Oncology reported preliminary Q4 FY2026 unit sales of 792 LYMPHIR units to U.S. wholesalers, a 120% increase from | Oct 26, 2026 |
| NRSN | 6-K | neutral | 3/10 | NeuroSense Therapeutics announced a strategic collaboration with an advisor to supply PrimeC, its ALS drug candidate, to | Oct 26, 2026 |